Carmegliptin

DB12268InvestigationalSmall molecule

Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.

Mechanism: Pharmacologically active on Dipeptidyl peptidase 4
Curator reviewed
Formula / weight: C₂₀H₂₈FN₃O₃ · 377.453 g/mol (avg)
Code names: R1579 · RO4876904

Resolves to

Compound

Structure

InChIKeyGUYMHFIHHOEFOA-ZCPGHIKRSA-NSMILES[H][C@@]1(CF)CN(C(=O)C1)[C@@]1([H])CN2CCC3=CC(OC)=C(OC)C=C3[C@]2([H])C[C@]1([H])N

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

656Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Carmegliptin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.